News

2021.01.08News Release

Atsushi Sugita Succeeds Koichi Takagi as President & CEO of Maruho

2020.12.21News Release

Maruho Announces Executive Personnel Changes and New Executive Structure

2020.07.09News Release

Maruho Announces New England Journal of Medicine Publication of Results from Phase 3 Clinical Study (Comparative Study) in Japan of Nemolizumab for the Treatment of Atopic Dermatitis

2020.04.01News Release

Maruho Announces Transfer/Acquisition of Device for Pincer Nails "Makizume Meister^®" Business and Establishment of the Medical Device Department

2019.12.10News Release

Maruho Enters an Exclusive License Agreement in Japan for SP-04, a Therapeutic Agent for Chemotherapy Induced Peripheral Neuropathy, and a Capital Alliance with Solasia

2019.12.02News Release

Chugai Completes Transfer of Rights to Maruho for Oxarol^® Ointment 25μg/g and Oxarol^® Lotion 25μg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris

2019.11.15News Release

Maruho Establishes New Research Base -Installation of Satellite Lab at Shonan iPark-

2019.09.09News Release

Maruho Preparing to Resume US Development For Anti-Herpes Virus Agent "Amenalief^® Tab. 200mg"

2019.07.31News Release

Maruho and KOSÉ Establish a Jointly Owned Company

2019.07.01News Release

Maruho Establishes New US Subsidiary,"Maruho America Inc."

2019.05.29News Release

Maruho and Welby Launch Smartphone App "Atopi Note" to Support Patients with Atopic Dermatitis

2019.04.18News Release

Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis

2019.03.29News Release

Maruho Announces a Transfer of Shares and a Change of a Consolidated Subsidiary

2019.03.04News Release

Maruho and Welby Launch Smartphone App "Nikibi Log" For Patients with Acne

2019.02.21News Release

Maruho and Asahi Kasei Pharma Announce First Approval in Japan of an Additional Dosage and Administration for Anti-herpes Virus Agent "Famvir^® Tab 250 mg" for the Treatment of Recurrent Herpes Simplex (Herpes labialis/Herpes genitalis)

2019.01.31News Release

Maruho and KOSÉ Agree to Establish a Jointly Owned Company